Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma

[1]  L. Licitra,et al.  Lenvatinib-induced renal failure: two first-time case reports and review of literature , 2018, Expert opinion on drug metabolism & toxicology.

[2]  M. Kudo,et al.  Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial , 2018, The Lancet.

[3]  M. Tahara,et al.  Optimal use of lenvatinib in the treatment of advanced thyroid cancer , 2017, Cancers of the Head & Neck.

[4]  J. Larkin,et al.  Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. , 2015, The Lancet. Oncology.

[5]  Wu-chang Yang,et al.  Diagnostic Accuracy of Urine Protein/Creatinine Ratio Is Influenced by Urine Concentration , 2015, PloS one.

[6]  Sung-Bae Kim,et al.  Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. , 2015, The New England journal of medicine.

[7]  Masao Iwata,et al.  Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. , 2013, Cancer letters.

[8]  S. Kashinakunti,et al.  Correlation of spot urine protein-creatinine ratio with 24-hour urinary protein in type 2 diabetes mellitus patients: A cross sectional study , 2011, Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences.

[9]  Pedagógia,et al.  Cross Sectional Study , 2019 .

[10]  J. Traynor,et al.  Assessing proteinuria in chronic kidney disease: protein-creatinine ratio versus albumin-creatinine ratio. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[11]  Yuji Yamamoto,et al.  E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition , 2008, International journal of cancer.

[12]  S. Garella,et al.  Use of single voided urine samples to estimate quantitative proteinuria. , 1983, The New England journal of medicine.

[13]  G. Deray,et al.  Hypertension and proteinuria: a class-effect of antiangiogenic therapies. , 2009, Anti-cancer drugs.